Published in J Biol Chem on April 15, 1993
Formation of mRNA 3' ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev (1999) 11.32
Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors. Mol Cell Biol (1995) 2.51
Presence of negative and positive cis-acting RNA splicing elements within and flanking the first tat coding exon of human immunodeficiency virus type 1. Mol Cell Biol (1994) 2.35
An intron enhancer containing a 5' splice site sequence in the human calcitonin/calcitonin gene-related peptide gene. Mol Cell Biol (1995) 1.67
Two different sequence elements within exon 4 are necessary for calcitonin-specific splicing of the human calcitonin/calcitonin gene-related peptide I pre-mRNA. Mol Cell Biol (1994) 1.64
A sequence compilation and comparison of exons that are alternatively spliced in neurons. Nucleic Acids Res (1994) 1.50
Role for Fox-1/Fox-2 in mediating the neuronal pathway of calcitonin/calcitonin gene-related peptide alternative RNA processing. Mol Cell Biol (2006) 1.41
A nuclear function of Hu proteins as neuron-specific alternative RNA processing regulators. Mol Biol Cell (2006) 1.31
Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet (2005) 0.95
Both U2 snRNA and U12 snRNA are required for accurate splicing of exon 5 of the rat calcitonin/CGRP gene. RNA (2004) 0.84
Complex transcriptional units: diversity in gene expression by alternative RNA processing. Annu Rev Biochem (1986) 4.73
Splice commitment dictates neuron-specific alternative RNA processing in calcitonin/CGRP gene expression. Cell (1987) 2.58
A candidate mouse model for Prader-Willi syndrome which shows an absence of Snrpn expression. Nat Genet (1992) 1.76
Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science (1985) 1.60
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci (1998) 1.59
Maternal imprinting of human SNRPN, a gene deleted in Prader-Willi syndrome. Nat Genet (1994) 1.45
The classification of dopamine receptors: relationship to radioligand binding. Annu Rev Neurosci (1983) 1.32
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A (1997) 1.26
Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron (1999) 1.19
Regulation of gene expression in vivo following transduction by two separate rAAV vectors. Nat Biotechnol (1998) 1.09
Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp Neurol (1999) 0.91
Age-related decreases in GTP-cyclohydrolase-I immunoreactive neurons in the monkey and human substantia nigra. J Comp Neurol (2000) 0.90
Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochem Pharmacol (1984) 0.88
A tissue-specific enhancer in the rat-calcitonin/CGRP gene is active in both neural and endocrine cell types. Mol Endocrinol (1990) 0.86
Interactions of novel dopaminergic ligands with D-1 and D-2 dopamine receptors. Life Sci (1982) 0.86
Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor. Mol Pharmacol (1985) 0.83
Agonist interactions with dopamine receptors: focus on radioligand-binding studies. Fed Proc (1984) 0.82
Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease. Exp Neurol (1997) 0.82
Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states. Mol Pharmacol (1985) 0.82
Dopamine receptor turnover rates in rat striatum are age-dependent. Proc Natl Acad Sci U S A (1984) 0.79
Dopaminergic D-3 binding sites are not presynaptic autoreceptors. Nature (1984) 0.78
Calcium, dexamethasone, and the antiglucocorticoid RU-486 differentially regulate neuropeptide synthesis in a rat C cell line. Endocrinology (1987) 0.77
Sulpiride isomers exhibit reversed stereospecificity for D-1 and D-2 dopamine receptors in the CNS. Neuropharmacology (1984) 0.77
Induction of c-fos, calcitonin gene expression, and acidic fibroblast growth factor production in a multipeptide-secreting neuroendocrine cell line. Endocrinology (1988) 0.77
Dopamine receptors in the central nervous system. Int Rev Neurobiol (1982) 0.76
Neuron-specific alternative RNA processing in neuroendocrine gene expression. Biochem Soc Trans (1987) 0.75
Dopamine receptors: a classification. J Clin Psychopharmacol (1982) 0.75
Dopamine receptors in the central nervous system. Adv Biochem Psychopharmacol (1983) 0.75
Solubilization of D-2 dopamine receptors from canine caudate: agonist-occupation stabilizes guanine nucleotide sensitive receptor complexes. Biochem Biophys Res Commun (1982) 0.75
Transmural ischemia during preexercise hyperventilation. Am J Cardiol (1983) 0.75